# MRC TE19/EORTC 30982: radiotherapy versus single-dose carboplatin as adjuvant treatment for stage I seminoma

Source: https://onco.cc/key-papers/paper-mrc-te19-carboplatin-seminoma-oliver-lancet-2005/  
OnCo record `paper-mrc-te19-carboplatin-seminoma-oliver-lancet-2005` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A single dose of carboplatin was as effective as radiotherapy in preventing relapse of stage I seminoma after orchidectomy, with less time off work and fewer second testicular cancers, so it replaced radiotherapy for men who choose adjuvant treatment.

## Summary

Phase 3 non-inferiority trial of 1,477 men with stage I seminoma randomised to adjuvant radiotherapy or one cycle of carboplatin (AUC 7).

Three-year relapse-free rates were 94.8 percent with carboplatin and 95.9 percent with radiotherapy (non-inferior), with fewer contralateral germ cell tumours after carboplatin and less acute toxicity; longer follow-up confirmed equivalence.

## Fields

- Kind: Key paper
- Last checked: 2026-09-17
- Journal: The Lancet
- Year: 2005
- DOI: 10.1016/S0140-6736(05)66984-X
- Authors: Oliver RT, Mason MD, Mead GM, et al.
- Findings: Three-year relapse-free rate 94.8 percent (carboplatin) vs 95.9 percent (radiotherapy); non-inferior.; Contralateral germ cell tumours 2 vs 10 cases.
- What it means: Single-dose carboplatin is the adjuvant option for stage I seminoma where surveillance is not chosen; radiotherapy is now rarely used because of second cancer risk.
- Caveats: Surveillance alone cures the same proportion of men after salvage and is preferred for most today.

## Sources

- Lancet 2005: https://doi.org/10.1016/S0140-6736(05)66984-X
- PubMed: https://pubmed.ncbi.nlm.nih.gov/16039331/

## Connected records

- cancers: [Seminoma](https://onco.cc/cancers/seminoma/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/)
- journals: [The Lancet](https://onco.cc/journals/lancet/)

---
JSON: https://onco.cc/api/v1/entities/paper-mrc-te19-carboplatin-seminoma-oliver-lancet-2005.json